Cargando…
MEDB-76. Evaluating the B7-H3 checkpoint in Medulloblastoma
BACKGROUND: There is currently no curative therapy for recurrent/refractory MB. Novel approaches to MB include immunotherapy, such as targeting the immune checkpoint molecule B7-H3. B7-H3 is implicated in tumor metastasis and is highly expressed in MB. This study explores the effects of genetically...
Autores principales: | Moziak, Kirsten, Picarda, Elodie, Perez, Natalia Muñoz, Galbo, Phillip, Zheng, Deyou, Zang, Xingxing, Martin, Allison |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164726/ http://dx.doi.org/10.1093/neuonc/noac079.450 |
Ejemplares similares
-
MEDB-33. The landscape of ecDNA in medulloblastoma
por: Chapman, Owen, et al.
Publicado: (2022) -
MEDB-31. THE CLINICAL SIGNIFICANCE OF EXTENT OF RESECTION IN MEDULLOBLASTOMA
por: Keeling, Claire, et al.
Publicado: (2022) -
MEDB-44. Transcriptomic resolution of subgroup-specific medulloblastoma architecture
por: Willard, Nicholas, et al.
Publicado: (2022) -
MEDB-72. MOLECULAR CHARACTERIZATION OF MEDULLOBLASTOMAS IN A SINGLE INSTITUTION
por: Tan, Enrica E K, et al.
Publicado: (2022) -
MEDB-23. Targeting epigenetic dysregulation in medulloblastoma with poor prognosis
por: Badodi, Sara, et al.
Publicado: (2022)